The hospital major's EBITDA surged 32.1% to ₹375.2 crore in Q3 FY25 over ₹284 crore year-on-year. Shares of Fortis Healthcare ...

Learn more about whether Bausch + Lomb Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...